| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.RADONC.2007.04.021 |
| P698 | PubMed publication ID | 17499868 |
| P50 | author | Jan Alsner | Q41699368 |
| Michael R. Horsman | Q47792821 | ||
| Jesper Grau Eriksen | Q57064572 | ||
| P2093 | author name string | Val Gebski | |
| Jens Overgaard | |||
| Marianne Nordsmark | |||
| P433 | issue | 3 | |
| P921 | main subject | head and neck carcinoma | Q18554836 |
| neck cancer | Q18966654 | ||
| advanced head and neck cancer | Q108565205 | ||
| P304 | page(s) | 389-397 | |
| P577 | publication date | 2007-05-17 | |
| P1433 | published in | Radiotherapy and Oncology | Q14251029 |
| P1476 | title | Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients | |
| P478 | volume | 83 |
| Q34512563 | A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers. |
| Q37617542 | Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis |
| Q39399506 | Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines |
| Q36678652 | Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials. |
| Q44624222 | Carbonic anhydrase-9 expression in head and neck cancer: a meta-analysis |
| Q33714638 | Clinical biomarkers for hypoxia targeting |
| Q38445971 | Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review |
| Q51470661 | Comparing the Effectiveness of Methods to Measure Oxygen in Tissues for Prognosis and Treatment of Cancer. |
| Q37676686 | Contribution of hypoxia-measuring molecular imaging techniques to radiotherapy planning and treatment. |
| Q28074577 | Current relevance of hypoxia in head and neck cancer |
| Q34173692 | Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells |
| Q33551004 | Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. |
| Q37306472 | Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer |
| Q52669828 | Hypoxia gene expression signatures as predictive biomarkers for personalising radiotherapy. |
| Q33477106 | Identification of osteopontin-dependent signaling pathways in a mouse model of human breast cancer |
| Q37989616 | Individualization of cancer treatment from radiotherapy perspective |
| Q39838585 | Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT. |
| Q36807138 | New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting |
| Q26749393 | Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis |
| Q39630464 | Quantitative Analysis of [18F]FMISO PET for Tumor Hypoxia: Correlation of Modeling Results with Immunohistochemistry. |
| Q27025579 | The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities |
| Q37187529 | The tumor microenvironment and metastatic disease |
| Q34474457 | Use of the comet-FISH assay to compare DNA damage and repair in p53 and hTERT genes following ionizing radiation |
Search more.